| |
Multiple field in field (Study group) |
Physical Wedge (Control group) |
P Value |
|
N= 75 |
N=75 |
|
| Age groups |
|
|
|
>25- <35
>35-<45
>45-<55
>55-<65
>65-<75 |
5 (6.7%)
24 (32. %)
36 (48%)
5 (6.7%)
5 (6.7%) |
5 (6.7%)
29 (38.7%)
23 (30.7%)
15 (20%)
3 (4%) |
0.065 |
| TNM Stage |
|
|
|
|
Stage I |
43 (57.3%) |
32 (42.7%) |
|
| Stage IIA |
28 (37.3 %) |
38 (50.7%) |
|
| Stage IIB |
2 (2.7%) |
3 (4%) |
0.344 |
| Stage IIIA |
2 (2.7%) |
2 (2.7%) |
|
| Chemotherapy |
|
|
|
|
No Chemotherapy |
4 (5.3%)
|
0 (0%) |
|
| AC X 4 Cycle |
40 (53.3%) |
50 (66.7%) |
0.211 |
| ACX4 Cycles +
Taxotere x4 Cycles |
22 (29.3%) |
16 (21.3%) |
|
| FEC X 6Cycles |
2 ( 2.7%) |
2 ( 2.7%) |
|
| TC x 6 cycles |
0 (0%) |
1 (1.3%) |
|
| ACX4 Cycles + Herceptin
Taxotere x4 Cycles |
7 (9.3%) |
6 (8%) |
|
| Hormones |
|
|
0.152 |
|
No Hormones |
20 (26.3%) |
14 (18.7%) |
|
| Tamoxifen |
47 (62.7%) |
45 (60%) |
|
| Letrozole |
8 (10.7%) |
16 (21.3%) |
|
|
Mean Whole Breast
PTV Volume ± SD |
1778.2 cc± 838 |
1705.4 cc ±889 |
0.103 |
